Sign In
Buy SHIEF
$0.0580
+0 (+0%)
At Close: Aug 10, 2026
Shield Therapeutics plc (SHIEF) Q2 2026 Sales/Trading Call Transcript
02:23pm, Thursday, 30'th Jul 2026
Shield Therapeutics plc (SHIEF) Q2 2026 Sales/Trading Call Transcript
Shield Therapeutics shares slip after interims, small-cap pharma says its still 'on-track'
05:42am, Thursday, 30'th Jul 2026
Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) told investors it remained profitable in the first half as a China milestone payment and higher royalties lifted revenue 41% to $30.4 million, with the
Shield Therapeutics plc (SHIEF) Q1 2026 Sales/Trading Call Transcript
03:51pm, Tuesday, 05'th May 2026
Shield Therapeutics plc (SHIEF) Q1 2026 Sales/Trading Call Transcript
Shield Therapeutics drops as CFO exits and Medicaid concerns weigh
05:06am, Friday, 01'st May 2026
Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) fell 12% to 7.71p after the group reported first-quarter revenue growth and positive earnings but...
Shield Therapeutics drops as CFO exits and Medicaid concerns weigh
04:16am, Friday, 01'st May 2026
Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) fell 12% to 7.71p after the group reported first-quarter revenue growth and positive earnings but flagged potential headwinds in the US market
Shield shares jump after FDA extends Accrufer exclusivity
09:51am, Monday, 09'th Feb 2026
Broker Cavendish says additional US protection strengthens long-term outlook and reiterates buy rating. Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) jumped as much 11% earlier in the sess
Shield Therapeutics plc (SHIEF) Q4 2025 Sales/Trading Call Transcript
03:24am, Friday, 23'rd Jan 2026
Shield Therapeutics plc (SHIEF) Q4 2025 Sales/Trading Call Transcript
Shield Therapeutics shares positive efficacy data for iron deficiency treatment
03:17am, Wednesday, 01'st Oct 2025
Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) has announced positive results from its Phase 3 pediatric FORTIS trial of ferric maltol (ACCRUFeR). The trial tested children and adolescents with iron
Shield Therapeutics lifted as US FDA extends Accufer approval
03:31am, Thursday, 04'th Sep 2025
Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) shares climbed in Thursday's early trade after it announced that the US Food and Drug Administration has accepted its submission to extend the label fo
Shield Therapeutics shares surge 21% as ACCRUFeR revenues double
07:48am, Wednesday, 23'rd Jul 2025
Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) saw its share price rise 21% following a strong second-quarter trading update. The company reported that net revenues from its iron deficiency treatment,
Shield Therapeutics rises on Japan licensing deal for iron deficiency drug
06:26am, Tuesday, 22'nd Apr 2025
Shares in Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) rose as much as 6% on Tuesday morning after the company announced a licensing agreement that will see its iron deficiency treatment ACCRUFeR b
Shield Therapeutics edges closer to profitability as US sales surge
05:14am, Tuesday, 25'th Feb 2025
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) is gaining momentum. The company, known for its oral iron supplement ACCRUFeR, has reported a strong end to 2024, with US sales driving record revenues f
Shield Therapeutics shares rise on the back of $10m fundraiser
11:49am, Friday, 06'th Dec 2024
Shares of Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) rose in afternoon trading after the company announced a $10 million fundraising commitment from its largest investor, AOP Health International.
Shield Therapeutics unveils premium fundraiser
07:54am, Friday, 06'th Dec 2024
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), a specialist in iron deficiency treatments, said its largest investor, AOP Health International, is backing a $10 million fundraiser. It will subscribe
Shield Therapeutics ‘on track for 2024' - analyst
09:22am, Thursday, 21'st Nov 2024
Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)'s proposed $10 million equity agreement with AOP Health International Management “should provide some much-needed breathing room” for the AIM-listed
